Companies Dominating the Peri-Implantitis Treatment Landscape
- Aetna Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Cadila Pharmaceuticals Limited
- R N Laboratories Pvt Ltd
- Neoss Limited
- Basic Pharma Lifesciences Pvt Ltd
- Dawood and Tanner
- Prachi Pharmaceuticals Private Limited
- Geistlich Pharma AG.
- Healthy Life Pharma Private Limited.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of peri-implantitis treatment is estimated at USD 2.63 billion.
The peri-implantitis treatment market size was valued at USD 2.33 billion in 2024 and is likely to cross USD 6.26 billion by 2037, registering more than 7.9% CAGR during the forecast period i.e., between 2025-2037. Growing consumption of cigarettes and increasing awareness of oral care will boost the market growth.
Asia Pacific industry is expected to hold largest revenue share by 2037, attributed to increasing prevalence of oral diseases, along with rising awareness regarding oral health.
The major players in the market are Aetna Inc., Pfizer Inc., Cadila Pharmaceuticals Limited, R N Laboratories Pvt Ltd, Neoss Limited, Basic Pharma Lifesciences Pvt Ltd, Dawood and Tanner, Prachi Pharmaceuticals Private Limited, Geistlich Pharma AG., Healthy Life Pharma Private Limited.
